Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

Topics: 

Citation
Shao SC, et al. Cardiovasc Diabetol 2019;18;(1):120.